Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models.

Choi JK, Carreras I, Dedeoglu A, Jenkins BG.

Neuropharmacology. 2010 Sep-Oct;59(4-5):353-7. doi: 10.1016/j.neuropharm.2010.03.011. Epub 2010 Apr 22.

2.

Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS.

Woo DC, Lee SH, Lee DW, Kim SY, Kim GY, Rhim HS, Choi CB, Kim HY, Lee CU, Choe BY.

Behav Brain Res. 2010 Jul 29;211(1):125-31. doi: 10.1016/j.bbr.2010.03.026. Epub 2010 Mar 20.

PMID:
20307581
3.

Combination therapy in a transgenic model of Alzheimer's disease.

Aytan N, Choi JK, Carreras I, Kowall NW, Jenkins BG, Dedeoglu A.

Exp Neurol. 2013 Dec;250:228-38. doi: 10.1016/j.expneurol.2013.10.001. Epub 2013 Oct 10.

4.

Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice.

Chen SQ, Wang PJ, Ten GJ, Zhan W, Li MH, Zang FC.

Dement Geriatr Cogn Disord. 2009;28(6):558-66. doi: 10.1159/000261646. Epub 2010 Jan 6.

5.

Treatment effects in a transgenic mouse model of Alzheimer's disease: a magnetic resonance spectroscopy study after passive immunization.

Marjańska M, Weigand SD, Preboske G, Wengenack TM, Chamberlain R, Curran GL, Poduslo JF, Garwood M, Kobayashi D, Lin JC, Jack CR Jr.

Neuroscience. 2014 Feb 14;259:94-100. doi: 10.1016/j.neuroscience.2013.11.052. Epub 2013 Dec 4.

6.

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.

Chen SQ, Cai Q, Shen YY, Wang PJ, Teng GJ, Zhang W, Zang FC.

Behav Brain Res. 2012 Nov 1;235(1):1-6. doi: 10.1016/j.bbr.2012.07.016. Epub 2012 Jul 22.

PMID:
22828014
7.

In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment.

Westman E, Spenger C, Oberg J, Reyer H, Pahnke J, Wahlund LO.

BMC Neurosci. 2009 Apr 7;10:33. doi: 10.1186/1471-2202-10-33.

8.

Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.

Griffith HR, den Hollander JA, Stewart CC, Evanochko WT, Buchthal SD, Harrell LE, Zamrini EY, Brockington JC, Marson DC.

NMR Biomed. 2007 Dec;20(8):709-16.

PMID:
17295394
9.

Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy.

Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR Jr, Ugurbil K, Garwood M.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11906-10. Epub 2005 Aug 9.

10.

Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1).

Esteras N, Alquézar C, Bartolomé F, Antequera D, Barrios L, Carro E, Cerdán S, Martín-Requero A.

J Alzheimers Dis. 2012;30(2):337-53. doi: 10.3233/JAD-2012-111967.

PMID:
22406445
11.

Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice.

Oberg J, Spenger C, Wang FH, Andersson A, Westman E, Skoglund P, Sunnemark D, Norinder U, Klason T, Wahlund LO, Lindberg M.

Neurobiol Aging. 2008 Sep;29(9):1423-33. Epub 2007 Apr 16.

PMID:
17434239
12.

Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.

Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF.

J Pharmacol Exp Ther. 2007 Aug;322(2):541-9. Epub 2007 May 15.

13.

Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.

Wu G, Miller RA, Connolly B, Marcus J, Renger J, Savage MJ.

Neurodegener Dis. 2014;14(2):53-66. doi: 10.1159/000353634. Epub 2013 Oct 23.

PMID:
24158021
14.

MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease.

Haris M, Singh A, Cai K, Nath K, Crescenzi R, Kogan F, Hariharan H, Reddy R.

J Neurosci Methods. 2013 Jan 15;212(1):87-93. doi: 10.1016/j.jneumeth.2012.09.025. Epub 2012 Oct 3.

15.

1H-MRS assessment of the therapeutic effect of bilateral intraventricular BDNF infusion into APP/PS1 double transgenic mice.

Zhang W, Wang PJ, Li MH, Wang GL, Li P, Gao XL.

J Mol Neurosci. 2013 Jul;50(3):434-42. doi: 10.1007/s12031-013-9951-5. Epub 2013 Jan 15.

PMID:
23315172
16.

Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease.

Hawkes CA, Deng LH, Shaw JE, Nitz M, McLaurin J.

Eur J Neurosci. 2010 Jan;31(2):203-13. doi: 10.1111/j.1460-9568.2009.07052.x. Epub 2010 Jan 13.

PMID:
20074226
17.

The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging.

Choi JK, Carreras I, Aytan N, Jenkins-Sahlin E, Dedeoglu A, Jenkins BG.

Brain Res. 2014 Nov 24;1590:85-96. doi: 10.1016/j.brainres.2014.09.067. Epub 2014 Oct 6.

18.

Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.

Nilsen LH, Melø TM, Saether O, Witter MP, Sonnewald U.

J Neurochem. 2012 Nov;123(4):532-41. doi: 10.1111/jnc.12003. Epub 2012 Oct 1.

19.

High cerebral scyllo-inositol: a new marker of brain metabolism disturbances induced by chronic alcoholism.

Viola A, Nicoli F, Denis B, Confort-Gouny S, Le Fur Y, Ranjeva JP, Viout P, Cozzone PJ.

MAGMA. 2004 Sep;17(1):47-61. Epub 2004 Aug 31.

PMID:
15340856
20.

Supplemental Content

Support Center